Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The FDA throws out the company’s second attempt at an accelerated approval.